Evidence map›Paper›PMID 40006065›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

Exploring the Aβ Plaque Microenvironment in Alzheimer's Disease Model Mice by Multimodal Lipid-Protein-Histology Imaging on a Benchtop Mass Spectrometer.

Elisabeth Müller, Thomas Enzlein, Dagmar Niemeyer, Livia von Ammon, Katherine Stumpo, Knut Biber, Corinna Klein, Carsten Hopf

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elisabeth MüllerCenter for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim University of Applied Sciences, 68163 Mannheim, Germany.ORCID 0000-0002-4787-9513
Thomas EnzleinCenter for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim University of Applied Sciences, 68163 Mannheim, Germany.ORCID 0000-0003-1789-4090
Dagmar NiemeyerBruker Daltonics GmbH & Co. KG, 28359 Bremen, Germany.
Livia von AmmonCenter for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim University of Applied Sciences, 68163 Mannheim, Germany.ORCID 0009-0006-4074-2289
Katherine StumpoBruker Scientific, LLC, Billerica, MA 01821, USA.
Knut BiberAbbVie Deutschland GmbH & Co. KG, 67061 Ludwigshafen, Germany.
Corinna KleinAbbVie Deutschland GmbH & Co. KG, 67061 Ludwigshafen, Germany.ORCID 0009-0003-4241-3284
Carsten HopfCenter for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim University of Applied Sciences, 68163 Mannheim, Germany.ORCID 0000-0003-0802-6451

Funding

AbbVie (Germany) privateFederal Ministry of Education and Research 13FH8I09IA
6 · The paper itself

Abstract

Amyloid-β (Aβ) plaque deposits in the brain are a hallmark of Alzheimer's disease (AD) neuropathology. Plaques consist of complex mixtures of peptides like Aβ

Indexed as

Alzheimer’s diseaseamyloid plaqueHiPLEX immunohistochemistrylipidMALDI mass spectrometry imagingmicroglia

Identifiers

PMID40006065
PMCPMC11860057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.